Oligonucleotide (siRNA) · Gene silencing: CIDEB · developed by Regeneron Pharmaceuticals
ALN-CIDEB is an siRNA-based agent that acts on CIDEB, the gene encoding cell death-inducing DFFA-like effector B, to lower its expression. It is being studied in metabolic dysfunction-associated steatotic liver disease (MASLD).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07854782 | Phase 3 | Metabolic Dysfunction-Associated Steatotic Liver Disease | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MASLDMetabolic Dysfunction-Associated Steatotic Liver Disease
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →